At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BVXV BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)
Not Yet Opened 09-06 16:00:00 EDT
1.36
+0.00
0.00%
High1.36Low1.36Vol0.00
Open1.36D1 Closing1.36Amplitude0.00%
Mkt Cap4.97MTradable Cap3.72MTotal Shares3.65M
T/O30.28KT/O Rate0.00%Tradable Shares2.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
GlobeNewswire  ·  2023-10-04
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
GlobeNewswire  ·  2023-09-20
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
BC Study Uncovers Cause of Four Major Pediatric Allergies
StreetInsider  ·  2023-09-08
BC Study Uncovers Cause of Four Major Pediatric Allergies
BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
StreetInsider  ·  2023-09-02
BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
Malaria Case Prompts Army to Ask Infectious Disease Experts to Analyze Mosquitoes
StreetInsider  ·  2023-09-01
Malaria Case Prompts Army to Ask Infectious Disease Experts to Analyze Mosquitoes
England Sees Soaring Numbers of Hospitalizations for Severe Allergies
StreetInsider  ·  2023-08-29
England Sees Soaring Numbers of Hospitalizations for Severe Allergies
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17
StreetInsider  ·  2023-08-26
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17
How Allergy Sufferers Can Benefit from Immunotherapy
StreetInsider  ·  2023-08-23
How Allergy Sufferers Can Benefit from Immunotherapy
Analyzing Link Between Hormonal Contraceptives, Autoimmunity
StreetInsider  ·  2023-08-19
Analyzing Link Between Hormonal Contraceptives, Autoimmunity
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment
StreetInsider  ·  2023-08-18
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
StreetInsider  ·  2023-08-17
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics
StreetInsider  ·  2023-08-15
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
StreetInsider  ·  2023-08-12
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
BiondVax Pharmaceuticals Q2 EPS $(0.003) Up From $(2.00) YoY
Benzinga  ·  2023-08-11
BiondVax Pharmaceuticals Q2 EPS $(0.003) Up From $(2.00) YoY
Press Release: BiondVax Reports Second Quarter Financial Results and Provides Business Update
Dow Jones  ·  2023-08-11
Press Release: BiondVax Reports Second Quarter Financial Results and Provides Business Update
How Immunotherapy Outcomes Can Be Affected by Diet, Gut Microbiota
StreetInsider  ·  2023-08-10
How Immunotherapy Outcomes Can Be Affected by Diet, Gut Microbiota
Study Finds Link Between Food Allergies in Infants, Childhood Asthma Onset
StreetInsider  ·  2023-08-04
Study Finds Link Between Food Allergies in Infants, Childhood Asthma Onset
Nasdaq grants BiondVax extension to regain compliance with listing rules
seekingalpha  ·  2023-08-02
Nasdaq grants BiondVax extension to regain compliance with listing rules
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets
StreetInsider  ·  2023-07-29
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets
M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
StreetInsider  ·  2023-07-27
M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

Introduction

Company Name.
BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Issue price:
--